Dr. An Bouwen
ActiveFrom the official registers: KBO 16 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
Dr. An Bouwen has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €438,734 and a net result of €113,848. Equity has been growing by about 48% per year since 2018. Its solvency ranks better than 89% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
KBO- Status
- Active since 13-10-2009 Normal situation
- Activity
- Specialist medical practice NACE 86220
- Establishment unit
- 2.294.117.603 8340 Damme, since 13-10-2009
- Financial year end
- 31 December
- Peppol
- Reachable since 10-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Gross margin
- €176,225
- ▲ 32.1%
- Turnover
- ≈ €330,000
- estimated
- Profit
- €113,848
- ▲ 37.0%
- Equity
- €438,734
- ▲ 35.0%
- Total assets
- €468,341
- ▲ 35.2%
Score breakdownlowers riskLiquidity: current ratio 15.14, cash €413,423Sector: Human health activities (NACE 86)Equity €438,734 (93.7% of total assets)Size: total assets €468,341Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 95% on liquidity, 60% on profitability and 74% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 50 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: Higher solvency than 89% of companies in human healthsector median 63.0% · 20,678 companies 93.7% View
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
- Positive: 8 profitable years in a rowprofit 2025: €113,848 8 years View
- Positive: Equity rose in 2025from €324,886 to €438,734 ▲ 35.0% View
Comparable companies
These companies have the same main activity as Dr. An Bouwen: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €439,000 and €490,000, founded between 2009 and 2012.
| Company | Total assets | Gross margin |
|---|---|---|
| Dr. An Bouwen Damme | €468,341 | €176,225 |
| DOKTER ANNE CLAEYS, OFTALMOLOGIE Beernem | €439,170 | €167,477 |
| Dokter Sophie Vanherpen Ronse | €482,343 | €175,993 |
| Dr. Willem Standaert Nazareth-De Pinte | €490,372 | €172,815 |
| DOKTER J. DE WACHTER Oud-Turnhout | €469,358 | €167,262 |
| DR SOCORRO ORTIZ Brussel | €465,221 | €166,093 |
| BV Dokter D.K. SOFTAM - Oftamologie Tielt-Winge | €483,445 | €176,150 |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 02-06-2026
- Annual accounts 2024filed on 02-06-2025
- Annual accounts 2023filed on 20-06-2024
- Annual accounts 2022filed on 23-06-2023
Acts in the Belgian Official Gazette
All publications in the Belgian Official GazetteArticles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about Dr. An Bouwen
- What is the company number of Dr. An Bouwen?
- The company number of Dr. An Bouwen is 0819.690.877. The VAT number is the same number with BE in front: BE 0819.690.877.
- Where is Dr. An Bouwen based?
- The registered office is at Koolkerkesteenweg 76, 8340 Damme.Company details
- What does Dr. An Bouwen do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of Dr. An Bouwen?
- The legal form of Dr. An Bouwen is Private limited company (BV).
- When was Dr. An Bouwen founded?
- Dr. An Bouwen was founded on 13-10-2009.
- Is Dr. An Bouwen still active?
- Yes, Dr. An Bouwen is an active enterprise in the KBO register.
- How many employees does Dr. An Bouwen have?
- Dr. An Bouwen had an average of 0.1 full-time equivalents in financial year 2020, according to the filed annual accounts.Financials
- What is the turnover of Dr. An Bouwen?
- The turnover in financial year 2025 is ≈ €330,000. This figure is estimated from the gross margin of €176,225 and 43 comparable companies (NACE 86220). It probably lies between €280,000 and €440,000.
- Is Dr. An Bouwen profitable?
- In financial year 2025, Dr. An Bouwen made a profit of €113,848.
- Where can I find the annual accounts of Dr. An Bouwen?
- Dr. An Bouwen filed 16 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
- When are the next annual accounts of Dr. An Bouwen due?
- Dr. An Bouwen must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.